Whalerock Point Partners LLC Acquires 680 Shares of Celgene Corporation (CELG)

Whalerock Point Partners LLC grew its holdings in Celgene Corporation (NASDAQ:CELG) by 3.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 20,793 shares of the biopharmaceutical company’s stock after acquiring an additional 680 shares during the period. Celgene Corporation comprises 1.0% of Whalerock Point Partners LLC’s holdings, making the stock its 17th biggest position. Whalerock Point Partners LLC’s holdings in Celgene Corporation were worth $2,701,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Celgene Corporation by 2.3% in the 1st quarter. State Street Corp now owns 32,473,417 shares of the biopharmaceutical company’s stock valued at $4,040,668,000 after acquiring an additional 723,844 shares during the last quarter. Jennison Associates LLC boosted its holdings in shares of Celgene Corporation by 1.2% in the 2nd quarter. Jennison Associates LLC now owns 13,415,734 shares of the biopharmaceutical company’s stock valued at $1,742,301,000 after acquiring an additional 156,864 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of Celgene Corporation by 4.9% in the 1st quarter. Bank of New York Mellon Corp now owns 10,088,473 shares of the biopharmaceutical company’s stock valued at $1,255,309,000 after acquiring an additional 472,067 shares during the last quarter. Pioneer Investment Management Inc. boosted its holdings in shares of Celgene Corporation by 15.7% in the 1st quarter. Pioneer Investment Management Inc. now owns 5,231,139 shares of the biopharmaceutical company’s stock valued at $650,911,000 after acquiring an additional 710,584 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in shares of Celgene Corporation by 24.1% in the 1st quarter. Clearbridge Investments LLC now owns 4,601,919 shares of the biopharmaceutical company’s stock valued at $572,617,000 after acquiring an additional 892,392 shares during the last quarter. 79.39% of the stock is currently owned by institutional investors and hedge funds.

CELG has been the topic of several recent research reports. Morgan Stanley downgraded shares of Celgene Corporation from an “equal weight” rating to an “underweight” rating and set a $120.00 price objective on the stock. in a report on Thursday, October 5th. BTIG Research reaffirmed a “hold” rating on shares of Celgene Corporation in a report on Sunday, October 22nd. Vetr raised shares of Celgene Corporation from a “buy” rating to a “strong-buy” rating and set a $144.39 price objective on the stock in a report on Monday, October 23rd. Barclays PLC dropped their price objective on shares of Celgene Corporation from $135.00 to $105.00 and set an “equal weight” rating on the stock in a report on Friday, October 20th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating on shares of Celgene Corporation in a report on Monday, August 28th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, nineteen have given a buy rating and two have assigned a strong buy rating to the stock. Celgene Corporation presently has an average rating of “Buy” and an average price target of $139.64.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.com-unik.info/2017/11/04/whalerock-point-partners-llc-acquires-680-shares-of-celgene-corporation-celg.html.

In other news, insider Terrie Curran sold 1,727 shares of the stock in a transaction on Monday, September 25th. The stock was sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the transaction, the insider now directly owns 3,925 shares in the company, valued at approximately $564,768.25. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Ernest Mario sold 18,506 shares of the stock in a transaction on Thursday, August 10th. The shares were sold at an average price of $130.52, for a total value of $2,415,403.12. Following the completion of the transaction, the director now owns 69,424 shares of the company’s stock, valued at $9,061,220.48. The disclosure for this sale can be found here. Insiders sold a total of 38,733 shares of company stock valued at $5,259,359 over the last quarter. 0.95% of the stock is owned by corporate insiders.

Celgene Corporation (NASDAQ CELG) opened at $100.04 on Friday. The company has a market capitalization of $77.31 billion, a price-to-earnings ratio of 15.34, a PEG ratio of 0.76 and a beta of 1.79. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. Celgene Corporation had a return on equity of 63.80% and a net margin of 27.36%. The company had revenue of $3.29 billion during the quarter, compared to analysts’ expectations of $3.42 billion. During the same period in the prior year, the company earned $1.58 EPS. Celgene Corporation’s revenue was up 10.2% compared to the same quarter last year. analysts predict that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.

Celgene Corporation Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

What are top analysts saying about Celgene Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit